{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:24:03Z","timestamp":1785381843963,"version":"3.55.0"},"reference-count":28,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20456"],"award-info":[{"award-number":["20456"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["PNRR-E.3-2022"],"award-info":[{"award-number":["PNRR-E.3-2022"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministero della Salute","award":["20456"],"award-info":[{"award-number":["20456"]}]},{"name":"Ministero della Salute","award":["PNRR-E.3-2022"],"award-info":[{"award-number":["PNRR-E.3-2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Blinatumomab alone or with donor leukocyte infusions (DLI) has been used after allogeneic hematopoietic stem cell transplantation (HSCT) as a salvage therapy in relapsing patients with CD19+ hematological malignancies. It was effective in a fraction of them, with low incidence of Graft-versus-Host Disease (GvHD). Immunosuppressive drugs used as GvHD prophylaxis hinder T cell function and reduce the efficacy of the treatment. Because T cell-depleted haploidentical HSCT with donor regulatory and conventional T cells (Treg\/Tcon haploidentical HSCT) does not require post-transplant immunosuppression, it is an ideal platform for the concomitant use of blinatumomab and DLI. However, the risk of GvHD is high because the donor is haploidentical. We treated two patients with CD19+ acute lymphoblastic leukemia (ALL) who had relapsed after Treg\/Tcon haploidentical HSCT with blinatumomab and DLI. Despite the mismatch for one HLA haplotype, they did not develop GvHD and achieved complete remission with negative minimal residual disease. Consistently, we found that blinatumomab did not enhance T cell alloreactivity in vitro. Eventually, the two patients relapsed again because of their high disease risk. This study suggests that treatment with blinatumomab and DLI can be feasible to treat relapse after haploidentical transplantation, and its pre-emptive use should be considered to improve efficacy.<\/jats:p>","DOI":"10.3390\/ijms242216105","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T03:42:08Z","timestamp":1699501328000},"page":"16105","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation"],"prefix":"10.3390","volume":"24","author":[{"given":"Antonella","family":"Mancusi","sequence":"first","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zorutti","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Azienda Ospedaliera S. Maria Della Misericordia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Bonato","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tricarico","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Zei","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Azienda Ospedaliera S. Maria Della Misericordia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Iacucci Ostini","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Azienda Ospedaliera S. Maria Della Misericordia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Viglione","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sembenico","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Sciabolacci","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Azienda Ospedaliera S. Maria Della Misericordia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cardinali","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Fabrizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mecucci","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carotti","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Azienda Ospedaliera S. Maria Della Misericordia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-1729","authenticated-orcid":false,"given":"Maria Paola","family":"Martelli","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Velardi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pierini","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Appelbaum, F.R., Forman, S.J., Negrin, R.S., and Blume, K.G. (2009). Thomas\u2019 Hematopoietic Cell Transplantation, Wiley-Blackwell Publishing. [4th ed.].","DOI":"10.1002\/9781444303537"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"Gruen","year":"2003","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase i\/phase ii study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"Locatelli","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA approval: Blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction Therapy Consolidation with Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults with First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3324\/haematol.2013.100073","article-title":"Pediatric posttransplant relapsed\/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab","volume":"99","author":"Schlegel","year":"2014","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia","volume":"25","author":"Handgretinger","year":"2011","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ccr3.604","article-title":"Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant","volume":"4","author":"Khan","year":"2016","journal-title":"Clin. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2016.104","article-title":"Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant","volume":"51","author":"Ueda","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2018-0104","article-title":"Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: A case report with literature review","volume":"11","author":"Durer","year":"2019","journal-title":"Immunotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41409-022-01846-9","article-title":"Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: A study of the SFGM-TC","volume":"58","author":"Chauvet","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2040620721994348","DOI":"10.1177\/2040620721994348","article-title":"Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma","volume":"12","author":"Smith","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Falzetti","year":"2011","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/bloodadvances.2020003739","article-title":"Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia","volume":"5","author":"Pierini","year":"2021","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1182\/blood-2013-03-489757","article-title":"A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease","volume":"121","author":"Meyer","year":"2013","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1182\/blood-2006-08-044529","article-title":"In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation","volume":"109","author":"Nguyen","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4049\/jimmunol.1402861","article-title":"Donor requirements for regulatory T cell suppression of murine graft-versus-host disease","volume":"195","author":"Pierini","year":"2015","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"ref_27","first-page":"146","article-title":"Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL","volume":"142","author":"Becilli","year":"2023","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/22\/16105\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:19:39Z","timestamp":1760131179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/22\/16105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":28,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ijms242216105"],"URL":"https:\/\/doi.org\/10.3390\/ijms242216105","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}